Cargando…
Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. Howev...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886307/ https://www.ncbi.nlm.nih.gov/pubmed/36726965 http://dx.doi.org/10.18632/genesandcancer.229 |
_version_ | 1784880107671781376 |
---|---|
author | Hannani, Dalil Leplus, Estelle Laulagnier, Karine Chaperot, Laurence Plumas, Joël |
author_facet | Hannani, Dalil Leplus, Estelle Laulagnier, Karine Chaperot, Laurence Plumas, Joël |
author_sort | Hannani, Dalil |
collection | PubMed |
description | In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells. |
format | Online Article Text |
id | pubmed-9886307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-98863072023-01-31 Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines Hannani, Dalil Leplus, Estelle Laulagnier, Karine Chaperot, Laurence Plumas, Joël Genes Cancer Research Perspective In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells. Impact Journals LLC 2023-01-30 /pmc/articles/PMC9886307/ /pubmed/36726965 http://dx.doi.org/10.18632/genesandcancer.229 Text en https://creativecommons.org/licenses/by/3.0/Copyright: © 2023 Hannani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Perspective Hannani, Dalil Leplus, Estelle Laulagnier, Karine Chaperot, Laurence Plumas, Joël Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
title | Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
title_full | Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
title_fullStr | Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
title_full_unstemmed | Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
title_short | Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
title_sort | leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines |
topic | Research Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886307/ https://www.ncbi.nlm.nih.gov/pubmed/36726965 http://dx.doi.org/10.18632/genesandcancer.229 |
work_keys_str_mv | AT hannanidalil leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines AT leplusestelle leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines AT laulagnierkarine leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines AT chaperotlaurence leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines AT plumasjoel leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines |